← Back to Screener
Definium Therapeutics, Inc. Common Shares (DFTX)
Price$23.18
Favorite Metrics
Price vs S&P 500 (26W)83.29%
Price vs S&P 500 (4W)13.77%
Market Capitalization$2.26B
All Metrics
Book Value / Share (Quarterly)$3.36
Cash Flow / Share (Quarterly)$-1.33
Price vs S&P 500 (YTD)65.24%
EPS (TTM)$-2.06
10-Day Avg Trading Volume1.65M
EPS Excl Extra (TTM)$-2.06
EPS (Annual)$-2.06
ROI (Annual)-49.29%
Cash / Share (Quarterly)$4.17
ROA (Last FY)-41.76%
EBITD / Share (TTM)$-2.11
ROE (5Y Avg)-64.36%
Cash Flow / Share (Annual)$-1.33
P/B Ratio6.80x
P/B Ratio (Quarterly)4.04x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-208.31x
ROA (TTM)-60.39%
EPS Incl Extra (Annual)$-2.06
Current Ratio (Annual)6.29x
Quick Ratio (Quarterly)6.17x
3-Month Avg Trading Volume1.88M
52-Week Price Return315.38%
Revenue / Employee (TTM)$0
52-Week High$23.41
EPS Excl Extra (Annual)$-2.06
26-Week Price Return92.04%
Quick Ratio (Annual)6.17x
13-Week Price Return51.00%
Total Debt / Equity (Annual)0.12x
Current Ratio (Quarterly)6.29x
Enterprise Value$2,043.896
Revenue / Employee (Annual)$0
Cash / Share (Annual)$4.17
3-Month Return Std Dev56.49%
Net Income / Employee (TTM)$-2
ROE (Last FY)-55.30%
Net Interest Coverage (Annual)-192.15x
EPS Basic Excl Extra (Annual)$-2.06
Total Debt / Equity (Quarterly)0.12x
EPS Incl Extra (TTM)$-2.06
ROI (TTM)-72.41%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)280.29%
Year-to-Date Return69.38%
5-Day Price Return1.93%
EPS Normalized (Annual)$-2.06
ROA (5Y Avg)-48.95%
Month-to-Date Return20.00%
EBITD / Share (Annual)$-2.12
LT Debt / Equity (Annual)0.12x
ROI (5Y Avg)-58.66%
LT Debt / Equity (Quarterly)0.12x
EPS Basic Excl Extra (TTM)$-2.06
P/B Ratio (Annual)4.04x
Book Value / Share (Annual)$3.36
Price vs S&P 500 (13W)48.13%
Beta2.49x
Revenue / Share (TTM)$0.00
ROE (TTM)-84.39%
52-Week Low$5.36
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.21
4.25
4.29
4.30
Industry Peers — Pharmaceutical Preparations(16)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
DFTXDefinium Therapeutics, Inc. Common Shares | — | — | — | — | $23.18 |
CRONCronos Group Inc. Common Share | 6.99x | 24.63% | 42.81% | -49.98% | $2.76 |
TLRYTilray Brands, Inc. Common Stock | 0.97x | 3.82% | 27.68% | — | $7.15 |
CGCCanopy Growth Corporation Common Shares | 2.55x | 0.59% | 26.56% | — | $1.20 |
NAGENiagen Bioscience, Inc. Common Stock | 3.01x | 29.95% | 64.28% | — | $4.87 |
USNAUSANA Health Sciences Inc | 0.41x | 5.88% | 78.29% | -37.04% | $20.64 |
SNDLSundial Growers Inc. Common Shares | 0.58x | 2.82% | 27.33% | — | $1.54 |
MDWDMediWound Ltd. | 13.35x | -16.14% | 19.19% | — | $17.35 |
ACBAurora Cannabis Inc. Common Shares | 0.77x | 16.54% | 1.35% | — | $3.72 |
BTMDBiote Corp. Class A Common Stock | 0.46x | -2.52% | 71.46% | -26.84% | $2.24 |
FTLFFitLife Brands, Inc. Common Stock | 1.29x | 1.34% | 37.58% | -20.04% | $8.99 |
About
Definium Therapeutics develops novel therapeutics targeting the underlying causes of psychiatric and neurological disorders, aiming for long-term patient remission rather than symptom management. Its pipeline includes four Phase 3 trials for generalized anxiety disorder (GAD) and major depressive disorder (MDD), led by DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. The company is advancing commercial and operational readiness ahead of potential product launch.